Michael Whyte is an Endocrinology/Metabolic physician. OpenAlex indexes 847 publications with 29,809 citations (h-index 87); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Bone & Mineral, Ste 5c
Saint Louis, MO 631101032
Telephone
314-454-7775Registry record last updated 15 Nov 2021.
Clinical trials
- Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)
Sponsor: Alexion Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KYOWA KIRIN, INC.Program year202513 payments$10,204openpaymentsdata.cms.gov ↗
- Kyowa Kirin, Inc.Program year202411 payments
- Novo Nordisk Health Care AGProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Vitamin D3 Analog56.7%Calcitriol100%Part D<11 patientsTissue-nonspecific Alkaline Phosphatase43.3%Strensiq100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1990–2002 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
The Lancet Diabetes & Endocrinology
2019 - Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial
The Lancet Diabetes & Endocrinology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Jens J. Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Daniel J. Drucker
University of Toronto
Kenneth Cusi, MD
University of Florida College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”